Learn more about whether Gilead Sciences, Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor ...

Foster City: Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir-the company’s twice-yearly ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--#GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health ...

16 analysts have shared their evaluations of Gilead Sciences GILD during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of ...

– Gilead Also Recently Submitted Applications for Lenacapavir for PrEP to the European Medicines Agency That Will Be Reviewed Under Accelerated Assessment Review Timeline – FOSTER CITY, ...

The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release. Gilead Sciences, Inc. recently announced that the FDA accepted its new drug ...

According to the Hebron Fire Department, at around 4:48 p.m. firefighters and troopers were deployed to the scene of Gilead Street for reports of a two-car accident involving a rollover.

Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of Gilead Sciences Inc (Symbol: GILD) were yielding above the 3% mark based on its quarterly dividend ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.

Analysts' ratings for Gilead Sciences GILD over the last quarter vary from bullish to bearish, as provided by 22 analysts. The following table encapsulates their recent ratings, offering a glimpse ...